Dynamic Technology Lab Private Ltd Acquires New Position in Enovis Co. (NYSE:ENOV)

Dynamic Technology Lab Private Ltd acquired a new position in shares of Enovis Co. (NYSE:ENOV) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 24,374 shares of the company’s stock, valued at approximately $1,050,000.

Other institutional investors also recently bought and sold shares of the company. Ridgewood Investments LLC purchased a new position in shares of Enovis during the 2nd quarter worth $44,000. DekaBank Deutsche Girozentrale acquired a new stake in shares of Enovis during the third quarter valued at about $55,000. Innealta Capital LLC purchased a new stake in shares of Enovis in the 2nd quarter valued at approximately $65,000. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Enovis by 28.1% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company’s stock worth $76,000 after acquiring an additional 371 shares during the last quarter. Finally, Heritage Family Offices LLP purchased a new position in shares of Enovis during the 3rd quarter worth approximately $206,000. 98.45% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ENOV. Needham & Company LLC reissued a “buy” rating and issued a $65.00 target price on shares of Enovis in a research report on Thursday, November 7th. Evercore ISI lowered their target price on Enovis from $62.00 to $58.00 and set an “outperform” rating for the company in a report on Tuesday, October 1st. JMP Securities assumed coverage on shares of Enovis in a research note on Thursday, October 3rd. They set an “outperform” rating and a $62.00 price target on the stock. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Enovis from $53.00 to $50.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $67.00.

Enovis Stock Performance

Shares of Enovis stock opened at $47.74 on Wednesday. The business has a 50-day simple moving average of $42.81 and a 200-day simple moving average of $44.90. The company has a market cap of $2.67 billion, a PE ratio of -21.80 and a beta of 1.91. Enovis Co. has a one year low of $38.27 and a one year high of $65.03. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.11. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The company had revenue of $505.22 million for the quarter, compared to the consensus estimate of $504.44 million. During the same period in the prior year, the firm posted $0.56 EPS. The company’s quarterly revenue was up 21.0% compared to the same quarter last year. On average, equities research analysts forecast that Enovis Co. will post 2.79 EPS for the current fiscal year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.